Criminal or bystander: imatinib and second primary malignancy in GIST patients

被引：8
作者：
Kanda, Tatsuo [1 ]
机构：
[1] Sanjo Gen Hosp, Sanjo City, Niigata 9550055, Japan
来源：
CHINESE JOURNAL OF CANCER RESEARCH | 2013年 / 25卷 / 05期
关键词：
GASTROINTESTINAL STROMAL TUMORS; NEOPLASMS; COEXISTENCE; KIT;
D O I：
10.3978/j.issn.1000-9604.2013.10.15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：490 / 492
页数：3
相关论文
共 50 条
  • [21] Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis
    Vincenzi, Bruno
    Nannini, Margherita
    Fumagalli, Elena
    Bronte, Giuseppe
    Frezza, Anna Maria
    De Lisi, Delia
    Ceruso, Mariella Spalato
    Santini, Daniele
    Badalamenti, Giuseppe
    Pantaleo, Maria Abbondanza
    Russo, Antonio
    Dei Tos, AngeloPaolo
    Casali, Paolo
    Tonini, Giuseppe
    ONCOTARGET, 2016, 7 (43) : 69412 - 69419
  • [22] Surgical Management in Metastatic Gastrointestinal Stromal Tumor (GIST) Patients After Imatinib Mesylate Treatment
    Yeh, Chun-Nan
    Chen, Tsung-Wen
    Tseng, Jeng-Hwei
    Liu, Yu-Yin
    Wang, Shang-Yu
    Tsai, Chun-Yi
    Chiang, Kun-Chun
    Hwang, Tsann-Long
    Jan, Yi-Yin
    Chen, Miin-Fu
    JOURNAL OF SURGICAL ONCOLOGY, 2010, 102 (06) : 599 - 603
  • [23] A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients
    Eechoute, Karel
    Fransson, Martin N.
    Reyners, An K.
    de Jong, Floris A.
    Sparreboom, Alex
    van der Graaf, Winette T. A.
    Friberg, Lena E.
    Schiavon, Gaia
    Wiemer, Erik A. C.
    Verweij, Jaap
    Loos, Walter J.
    Mathijssen, Ron H. J.
    De Giorgi, Ugo
    CLINICAL CANCER RESEARCH, 2012, 18 (20) : 5780 - 5787
  • [24] An unusual and potentially misleading phenotypic change in a primary gastrointestinal stromal tumour (GIST) under imatinib mesylate therapy
    Nikolaos Vassos
    Abbas Agaimy
    Anne Schlabrakowski
    Werner Hohenberger
    Regine Schneider-Stock
    Roland S. Croner
    Virchows Archiv, 2011, 458 : 363 - 369
  • [25] Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure
    Bins, Sander
    Eechoute, Karel
    Kloth, Jacqueline S. L.
    de Man, Femke M.
    Oosten, Astrid W.
    de Bruijn, Peter
    Sleijfer, Stefan
    Mathijssen, Ron H. J.
    CLINICAL PHARMACOKINETICS, 2017, 56 (03) : 305 - 310
  • [26] Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability
    Kim, Kyu-pyo
    Ryu, Min-Hee
    Yoo, Changhoon
    Ryoo, Baek-Yeol
    Choi, Dae Ro
    Chang, Heung Moon
    Lee, Jae-Lyun
    Beck, Mo Youl
    Kim, Tae Won
    Kang, Yoon-Koo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (02) : 285 - 291
  • [27] An unusual and potentially misleading phenotypic change in a primary gastrointestinal stromal tumour (GIST) under imatinib mesylate therapy
    Vassos, Nikolaos
    Agaimy, Abbas
    Schlabrakowski, Anne
    Hohenberger, Werner
    Schneider-Stock, Regine
    Croner, Roland S.
    VIRCHOWS ARCHIV, 2011, 458 (03) : 363 - 369
  • [28] Long-Surviving Patients with Recurrent GIST after Receiving Cytoreductive Surgery with Imatinib Therapy
    Choi, Won Hyuk
    Kim, Sungsoo
    Hyung, Woo Jin
    Yu, Jeong Sik
    Park, Chan Il
    Choi, Seung Ho
    Noh, Sung Hoon
    YONSEI MEDICAL JOURNAL, 2009, 50 (03) : 437 - 440
  • [29] Second Primary Malignancy Risk in Multiple Myeloma from 1975 to 2018
    Wang, Jing
    Lv, Chenglan
    Zhou, Min
    Xu, Jing-Yan
    Chen, Bing
    Wan, Yuan
    CANCERS, 2022, 14 (19)
  • [30] Development of second primary malignancy in patients with non-Hodgkin lymphoma: a nationwide population-based study
    Chien, Sheng-Hsuan
    Liu, Chia-Jen
    Hong, Ying-Chung
    Teng, Chung-Jen
    Hu, Yu-Wen
    Ku, Fan-Chen
    Yeh, Chiu-Mei
    Chiou, Tzeon-Jye
    Gau, Jyh-Pyng
    Tzeng, Cheng-Hwai
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (11) : 1995 - 2004
12345